A Phase 2 interventional study of SAR440340 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Sanofi. Completed at 83 sites in 10 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-22.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.
Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 2, and was the 1st registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 40+
Sanofi · Sites in France
Ages 18+
Sanofi · Sites in United States, Argentina, Austria and 19 more countries
Ages 40–85
Sanofi · Sites in United States, Argentina, Australia and 23 more countries
Ages 40–80
Sanofi · Sites in United States, Argentina, Belgium and 22 more countries
Ages 40–80
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2018.
This study's enrollment of 343 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 937 across the 12 interventional studies, 350 across the 3 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To investigate effects of SAR440340 (anti-interleukin-33 [IL-33] monoclonal antibody [mAb]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52 weeks of treatment.
Secondary Objectives:
To investigate effects of SAR440340 compared with placebo, on improving respiratory function, as assessed by pre-bronchodilator forced exploratory volume in 1 second (FEV1).
To evaluate effects of SAR440340 compared with placebo, on post-bronchodilator FEV1.
To evaluate effects of SAR440340 compared with placebo, on duration from baseline to first moderate or severe AECOPD event.
To evaluate effects of SAR440340 compared with placebo, on safety and tolerability.
Study participation for each participant were up to a total of 46 weeks to 76 weeks including up to 10 days to 4 weeks of screening, 24-to-52 week treatment period on investigational medical product (IMP), and 20 weeks of post IMP treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to SAR440340 administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W). Participants were treated for a minimum of 24 weeks and up to a maximum of 52 weeks (last dose administered at Week 50, End of Treatment (EOT) visit occurred 2 weeks after last administration of IMP i.e., at Week 52).
Drug: Placebo · Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care · Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care · Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care · Drug: Any short-acting β agonist as prescribed by treating physician as standard of care
Participants received SAR440340 300 milligrams (mg) administered as 2 SC injections Q2W. Participants were treated for a minimum of 24 weeks and up to a maximum of 52 weeks (last dose administered at Week 50, EOT visit occurred 2 weeks after last administration of IMP i.e., at Week 52).
Drug: SAR440340 · Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care · Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care · Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care · Drug: Any short-acting β agonist as prescribed by treating physician as standard of care
Pharmaceutical form: Solution for injection; Route of administration: SC
Also known as: Itepekimab, REGN3500
Pharmaceutical form: Solution for injection; Route of administration: SC
Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
Annualized Rate of Moderate to Severe Acute Exacerbation Events in Chronic Obstructive Pulmonary Disease (AECOPD) Participants
Moderate exacerbations events were recorded by the investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations events were defined as AECOPD requiring hospitalization, emergency medical care visit or resulting in death. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time frame: From Baseline up to Week 52
Average Change in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Week 16 Through Week 24
FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. A mixed-effect model with repeated measures (MMRM) was first used to model the change from baseline at each post randomization timepoint up to Week 24, then the predicted values of Week 16 to Week 24 were averaged to provide an overall assessment of change from baseline in FEV1.
Time frame: From Baseline to Week 16 through Week 24
Change From Baseline in Post-bronchodilator Forced Expiratory Volume (FEV1) in 1 Second at Week 24
FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-bronchodilator FEV1 referred to the spirometry performed within 30 minutes after administration of bronchodilator (4 puffs of salbutamol/albuterol \[100 micrograms {mcg}\] or ipratropium bromide \[20 mcg\]).
Time frame: Baseline, Week 24
Time to First Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
The time to first moderate or severe exacerbation was defined as onset date of first moderate or severe AECOPD minus randomization date + 1. The median time to first severe exacerbation was derived from Kaplan-Meier estimates. Moderate exacerbations events were recorded by the investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations events were defined as AECOPD requiring hospitalization, emergency medical care visit or resulting in death.
Time frame: From Baseline up to 52 weeks
The study was conducted at 83 centers in 10 countries, out of which 78 centers randomized at least 1 participant. A total of 653 participants were screened from 16-July-2018 to 01-April-2019, of which 310 participants were screen failures mainly due to selection criteria not met.
| Milestone | Placebo | SAR440340 |
|---|---|---|
| Started | 171 | 172 |
| Completed | 154 | 151 |
| Not completed | 17 | 21 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Withdrawal by subject | 8 | 9 |
| Withdrew: Adverse events (aes) | 7 | 10 |
| Withdrew: Other-unspecified | 1 | 1 |
Moderate exacerbations events were recorded by the investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations events were defined as AECOPD requiring hospitalization, emergency medical care visit or resulting in death. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
| exacerbation per participant-year | Placebo | SAR440340 |
|---|---|---|
| Annualized Rate of Moderate to Severe Acute Exacerbation Events in Chronic Obstructive Pulmonary Disease (AECOPD) Participants | 1.610 (1.318 to 1.968) | 1.301 (1.052 to 1.61) |
FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. A mixed-effect model with repeated measures (MMRM) was first used to model the change from baseline at each post randomization timepoint up to Week 24, then the predicted values of Week 16 to Week 24 were averaged to provide an overall assessment of change from baseline in FEV1.
| liters | Placebo | SAR440340 |
|---|---|---|
| Average Change in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) From Baseline to Week 16 Through Week 24 | 0.0 ± 0.02 | 0.06 ± 0.02 |
FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-bronchodilator FEV1 referred to the spirometry performed within 30 minutes after administration of bronchodilator (4 puffs of salbutamol/albuterol \[100 micrograms {mcg}\] or ipratropium bromide \[20 mcg\]).
| liters | Placebo | SAR440340 |
|---|---|---|
| Change From Baseline in Post-bronchodilator Forced Expiratory Volume (FEV1) in 1 Second at Week 24 | 0.01 ± 0.22 | 0.04 ± 0.24 |
The time to first moderate or severe exacerbation was defined as onset date of first moderate or severe AECOPD minus randomization date + 1. The median time to first severe exacerbation was derived from Kaplan-Meier estimates. Moderate exacerbations events were recorded by the investigator and defined as AECOPD that require either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. Severe exacerbations events were defined as AECOPD requiring hospitalization, emergency medical care visit or resulting in death.
| days | Placebo | SAR440340 |
|---|---|---|
| Time to First Moderate or Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) | 199.0 (139.00 to 266.00) | 277.0 (204.00 to NA) |
Collected over From first administration of IMP up to 22 weeks after last dose of IMP (i.e., minimum up to 46 weeks and a maximum of up to 72 weeks) regardless of seriousness or relationship to IMP. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 2/171 (1.2%) | 36/171 (21.1%) | 78/171 (45.6%) |
| SAR440340 | 3/172 (1.7%) | 29/172 (16.9%) | 60/172 (34.9%) |
| Event | Placebo | SAR440340 |
|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 14/171 | 11/172 |
| Infective Exacerbation Of Chronic Obstructive Airways DiseaseInfections and infestations | 5/171 | 1/172 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 4/171 | 0/172 |
| PneumoniaInfections and infestations | 3/171 | 2/172 |
| Transient Ischaemic AttackNervous system disorders | 2/171 | 0/172 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 2/171 | 0/172 |
| Cardiac Failure CongestiveCardiac disorders | 1/171 | 2/172 |
| BronchitisInfections and infestations | 0/171 | 2/172 |
| Arteriosclerosis Coronary ArteryCardiac disorders | 1/171 | 0/172 |
| Myocardial InfarctionCardiac disorders | 1/171 | 0/172 |
| Event | Placebo | SAR440340 |
|---|---|---|
| NasopharyngitisInfections and infestations | 29/171 | 28/172 |
| HeadacheNervous system disorders | 23/171 | 14/172 |
| BronchitisInfections and infestations | 14/171 | 16/172 |
| Upper Respiratory Tract InfectionInfections and infestations | 14/171 | 13/172 |
| HypertensionVascular disorders | 11/171 | 3/172 |
Randomized population included any participant who had signed informed consent and had been allocated to a randomized treatment regardless of whether the treatment kit was used.
| Age, Continuous(years) | Placebo | SAR440340 | Total |
|---|---|---|---|
| Mean | 64.0 ± 6.5 | 63.7 ± 6.8 | 63.9 ± 6.7 |
| Sex: Female, Male(Participants) | Placebo | SAR440340 | Total |
|---|---|---|---|
| Female | 76 | 73 | 149 |
| Male | 95 | 99 | 194 |
| Race (NIH/OMB)(Participants) | Placebo | SAR440340 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 169 | 170 | 339 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Age at diagnosis of chronic obstructive pulmonary disease (COPD)(years) | Placebo | SAR440340 | Total |
|---|---|---|---|
| Mean | 55.5 ± 8.0 | 55.4 ± 7.8 | 55.4 ± 7.9 |
| Mean number of moderate COPD exacerbations experienced within 1 year before screening visit(exacerbations) | Placebo | SAR440340 | Total |
|---|---|---|---|
| Mean | 1.8 ± 1.2 | 1.8 ± 1.1 | 1.8 ± 1.2 |
| Mean number of severe COPD exacerbations experienced within 1 year before screening visit(exacerbations) | Placebo | SAR440340 | Total |
|---|---|---|---|
| Mean | 0.4 ± 0.6 | 0.3 ± 0.6 | 0.4 ± 0.6 |
| Number of participants with smoking history(Participants) | Placebo | SAR440340 | Total |
|---|---|---|---|
| Current | 82 | 74 | 156 |
| Former | 89 | 98 | 187 |
| Predicted baseline post-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)(percent predicted FEVI) | Placebo | SAR440340 | Total |
|---|---|---|---|
| Mean | 49.02 ± 12.18 | 49.62 ± 12.34 | 49.32 ± 12.25 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jul 2018 to primary completion in Oct 2019, 14 months.
Results were first posted in Nov 2022, 3 years 1 month after primary completion. A results delay was requested in Sep 2020.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 14 months is close to that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Itepekimab
Pulmonary Disease, Chronic Obstructive →